Warning: Undefined array key "file" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Warning: Undefined array key "title" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Warning: Undefined array key "title" in /home/www/wwwroot/HTML/www.exportstart.com/wp-content/themes/1198/header.php on line 7

Vorinostat CAS 149647-78-9

High Quality Antineoplastic Drugs Chemical Powder Vorinostat CAS 149647-78-9

 

  • Isem tal-prodott:

    Vorinostat CAS 149647-78-9

  • Grad:

    Pharmaceutical grade/Cosmetic grade

  • Proprjetajiet:

    trab abjad

  • Ippakkjar:

    25kg/tanbur

  • MOQ:

    1 kilo

  • Ħażna:Kessaħ Post Niexef
  • Żmien kemm idum tajjeb:2 snin


Dettalji

Tikketti

Deskrizzjoni tal-prodott

Vorinostat is a potent HDAC inhibitor with significant applications in cancer treatment, regulating gene expression, and potentially antiviral activities.

  1. HDAC Inhibition: Vorinostat functions by specifically binding to and inhibiting HDAC, including HDAC1, HDAC2, HDAC3 (Class I), and HDAC6 (Class II), thereby altering the acetylation status of histones and other proteins.
  2. Gene Expression Regulation: By inhibiting HDAC activity, Vorinostat helps to restore normal gene expression patterns, which are often disrupted in cancer cells. This leads to cell cycle arrest and apoptosis (programmed cell death) in cancer cells.
  3. Antiviral Activity: Studies have also shown that Vorinostat has the potential to reactivate latent HIV virus in patients, although further research is needed to fully understand and exploit this antiviral property in clinical settings.

 

 

Applikazzjoni
  1. Anticancer Drug: Vorinostat is primarily utilized as an anticancer agent, particularly in the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin's lymphoma that has worsened, persisted, or recurred after two systemic therapies.
  2. FDA Approval: It was approved by the U.S. Food and Drug Administration (FDA) in October 2006 for the treatment of skin cancer, marking it as the first FDA-approved drug for metastatic CTCL when other therapies have failed, the disease has worsened, or has returned.
  3. Combination Therapy: Vorinostat can also be used in combination with other antitumor drugs to enhance their synergistic effects.

 

Vantaġġi

Għandna ħafna fabbriki ta 'kwalità għolja b'kooperazzjoni profonda, li jistgħu jagħtuk prodotti ta' kwalità għolja u prezzijiet kompetittivi. U nistgħu wkoll nagħtu skontijiet għal xiri bl-ingrossa. U aħna nikkooperaw ma 'ħafna kumpaniji professjonali tal-ġarr tal-merkanzija, nistgħu nwasslu prodotti b'mod sikur u bla xkiel f'idejk. Il-ħin tal-kunsinna huwa ta 'madwar 3-20 jum wara l-konferma tal-ħlas.

 

Speċifikazzjoni

 

Tbaħħir u ħlas


 

FAQ

1. Inti fabbrika jew kumpanija kummerċjali?
Aħna kumpanija li tintegra l-industrija u l-kummerċ, li nipprovdu servizz one-stop. OEM jista 'jiġi aċċettat.

2. Inti tipprovdi kampjuni? Huwa b'xejn jew żejjed?
Kampjuni b'xejn. It-tariffa tal-merkanzija tal-kampjun trid titħallas min-naħa tiegħek.

3. Għandek xi ċertifikati relatati mal-kontroll tal-kwalità?
Ċertifikazzjoni ISO 9001:2008 biex tiġi żgurata l-kwalità.

4. X'għandi nipprovdi biex tikseb kwotazzjoni?
PLS għarrafna bit-tip ta 'prodott li għandek bżonn, kwantità tal-ordni, indirizz u rekwiżiti speċifiċi. Il-kwotazzjoni ssir għar-referenza tiegħek fil-ħin.

5. X'tip ta 'metodu ta' ħlas tippreferi? X'tip ta' termini huma aċċettati?
Termini ta ' Kunsinna Aċċettati: FOB, CFR, CIF, EXW;
Munita ta 'Ħlas Aċċettata: USD;
Accepted Payment Type: T/T,Western Union; Paypal,BTC
Lingwa Mitkellma: Ingliż.

 

Jekk inti interessat fil-prodotti tagħna, tista 'tagħżel li tħalli l-informazzjoni tiegħek hawn, u aħna ser inkunu f'kuntatt miegħek dalwaqt.


Ikteb il-messaġġ tiegħek hawn u ibgħatilna